Composition for improving long-term memory and cognitive function comprising intestinal microorganisms as active ingredient
A composition containing Prevotella loescheii and Odoribactor splanchnicus addresses the gap in intestinal microorganisms' impact on cognitive function by enhancing beneficial gut bacteria, improving long-term memory and cognitive function, effectively countering stress-induced cognitive decline.
Patent Information
- Application Number
- PCT/KR2024/007412
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Current studies have not adequately identified intestinal microorganisms' impact on cognitive function through the gut-brain axis, and stress-related gut dyshomeostasis can lead to reduced cognitive function, with limited effective solutions for improving long-term memory and cognitive dysfunction.
A composition containing Prevotella loescheii and Odoribactor splanchnicus as active ingredients, isolated from healthy and exercised mice, is used to improve cognitive function by restoring intestinal homeostasis through fecal microbiota transplantation, enhancing beneficial bacteria and reducing harmful bacteria in the gut, thereby improving long-term memory and cognitive function.
The composition significantly improves long-term memory and cognitive function by increasing beneficial bacteria like Prevotella loescheii and decreasing harmful bacteria like Odoribactor splanchnicus, mirroring the effects of exercise on mice under stress, offering a therapeutic agent for cognitive dysfunction and intestinal flora improvement.
Smart Images

Figure KR2024007412_05122024_PF_FP_ABST
Abstract
Description
A composition for improving long-term memory and cognitive function containing intestinal microorganisms as an active ingredient
[0001] This application was made with the support of the Ministry of Education of the Republic of Korea under the project identification number 1345314553 and project number 2018R1D1A3B07048502. The research management specialized institution of the project is the National Research Foundation of Korea, the research project name is “Establishment of Science and Engineering Research Infrastructure (R&D)”, the research project name is “Effects of aerobic exercise and healthy fecal microbiota transplantation on cognitive function in an animal model of irritable bowel syndrome caused by infant stress”, the project implementing institution is Gyeongnam National University, and the research period is 2020.03.01-2020.05.31.
[0002] In addition, this application was made under the support of the Ministry of Education of the Republic of Korea under the project identification number 1345376871 and project number BRIDGE-2023-B18. The research management specialized organization of the said project is the National Research Foundation of Korea, the research project name is "Support for Advanced Industry-Academic Cooperation", the research project name is "University Creative Asset Commercialization Support (BRIDGE3.0) Project", the project implementing organization is Inje University, and the research period is 2023.03.01-2024.02.29.
[0003] This patent application claims priority to Republic of Korea Patent Application No. 10-2023-0071161, filed with the Korean Intellectual Property Office on June 1, 2023, the disclosure of which is incorporated herein by reference.
[0004] The present invention relates to a composition for improving long-term memory and cognitive function, which contains intestinal microorganisms as an effective ingredient.
[0005]
[0006] Recent research has revealed that gut microbiota plays a crucial role in the bidirectional communication between the gut and the brain, mediated by the endocrine, nervous, and immune systems. This is known as the gut-brain axis. Detailed mechanisms are being identified, demonstrating that changes in gut microbiota composition and metabolites directly influence not only appetite, sleep, and mood regulation, but also brain functions such as long-term memory and learning, through mechanisms such as systemic immunity, hormones, and neurotransmitters. Furthermore, as the relationship between the gut and the brain becomes clearer, research is increasingly revealing the role of gut microbiota in various brain diseases.
[0007] Stress associated with the hypothalamic-pituitary-adrenal axis is known to affect the composition of the gut microbiota. This stress has been reported to induce pathophysiological changes in the gut, the creation of new bacteria, and changes in the gut microbiota due to the release of stress hormones. Gut dyshomeostasis resulting from such stressful situations can lead to gut-brain axis dysfunction, which is considered a significant factor in the decline of cognitive function.
[0008] Exercise improves cognitive function by structurally and functionally altering the brain through neurogenesis, angiogenesis, increased levels of nerve growth factors and neurotransmitters, and the promotion of synaptic connections. Furthermore, exercise stimulates neurogenesis in the hippocampus, which is suppressed by stress, and inhibits accelerated cell death. Numerous studies have reported that these effects of exercise and cognitive function have shown significant results not only in healthy infants, adolescents, adults, and the elderly, but also in patients with medical conditions.
[0009] Meanwhile, restoration of intestinal homeostasis through fecal microbiota transplantation has been successfully used to treat various diseases, including colitis, irritable bowel syndrome, and idiopathic constipation. Furthermore, it has been reported that 70% of IBS patients experienced improvement or relief from symptoms such as abdominal pain, diarrhea, and abdominal bloating after fecal microbiota transplantation. These results suggest the potential for gut microbiota to directly influence intestinal function and behavior.
[0010] Currently, there are not many studies that have confirmed the relationship between gut microbes and cognitive function based on the gut-brain axis theory, and the discovery of related candidate microbes is expected to have a significant impact on the economy and society.
[0011]
[0012] The present inventors have conducted extensive research to determine whether intestinal microbiota transplantation in mice that exercised would improve cognitive function deteriorated by stress, and to discover microorganisms as effective ingredients related to cognitive function enhancement. As a result, they found that while mice under stress due to maternal separation showed a significant decrease in long-term memory and cognitive function, those receiving intestinal microbiota transplantation from healthy or exercised mice showed a significant increase in long-term memory and cognitive function. These effects were confirmed to be related to the beneficial bacterium Prevotella loescheii and the harmful bacterium Odoribactor splanchnicus among the intestinal microbiota. Furthermore, to confirm once again whether the single beneficial bacterium 'Prevotella loescheii' discovered directly affects long-term memory and cognitive function, they transplanted it into healthy mice, and as a result, they found that it improved long-term memory and cognitive function, thereby completing the present invention.
[0013] Accordingly, the purpose of the present invention is to provide a composition containing intestinal microorganisms as an effective ingredient for improving cognitive function deteriorated due to stress.
[0014]
[0015] According to one aspect of the present invention, the present invention provides a food composition comprising Prevotella loescheii as an active ingredient.
[0016] The present inventors analyzed the intestinal microbiota of mice and found that Prevotella loescheii significantly decreased in the intestinal microbiota of mice subjected to maternal separation stress, but significantly increased in the group that received intestinal microbiota transplanted from healthy or exercised mice. On the other hand, Odoribactor splanchnicus significantly increased in the intestinal microbiota of mice subjected to maternal separation stress, and significantly decreased in the group that received intestinal microbiota transplanted from healthy or exercised mice. In addition, we found that direct transplantation of Prevotella loescheii microorganisms into mice improved cognitive function.
[0017] As used herein, the term "long-term memory" is the opposite of "short-term memory," which refers to information being retained for hours, days, weeks, or even years without being lost. In contrast, "short-term memory" refers to a storage method in which information is retained for a few minutes or seconds.
[0018] As used herein, the term "cognitive function" includes the above 'long-term memory' and means, for example, memory, attention, time perception, spatial perception, language ability, judgment, or a combination thereof.
[0019] In one embodiment of the present invention, the Prevotella loescheii is isolated from the intestine of an animal.
[0020] In one embodiment of the present invention, the Prevotella rushii is deposited at the “Korea Center for Microorganism Conservation (KCCM)” under the accession number “KCCM 42828.”
[0021] The above Prevotella rashi is a facultative anaerobic bacterium, which is generally found in the intestines or oral cavity, and its optimal growth temperature is 36-38℃.
[0022] The 16s rRNA sequence of the above strain is represented by the nucleotide sequence of SEQ ID NO: 1. The sequence is registered in GenBank as AB547688.
[0023] When the composition of the present invention is manufactured as a food composition, it may include not only the intestinal bacteria as an active ingredient, but also ingredients commonly added during food manufacturing. The added ingredients include, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. The carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, oligosaccharides, etc.), and polysaccharides (e.g., conventional sugars such as dextrin, cyclodextrin, etc., and sugar alcohols such as xylitol, sorbitol, erythritol, etc.). Natural flavoring agents (thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
[0024] For example, when the food composition of the present invention is manufactured into a drink, in addition to the strain, which is an effective ingredient of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, jujube extract, or licorice extract, etc. may be additionally included.
[0025] The food composition of the present invention includes processed forms of all food materials, such as foods, functional foods, nutritional supplements, health foods, health functional foods, and food additives. The food composition of the above type can be manufactured in various forms according to conventional methods known in the art.
[0026] For example, as a health food, the lactic acid bacteria itself can be manufactured in the form of tea, juice, and drinks and consumed, or can be granulated, encapsulated, and powdered and consumed. In addition, as a food, beverages (including alcoholic beverages), fruits and processed foods thereof (e.g., canned fruits, bottled fruits, jams, marmalades, etc.), fish, meats and processed foods thereof (e.g., ham, sausages, corned beef, etc.), breads and noodles (e.g., udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, taffy, dairy products (e.g., yogurt, fermented milk, butter, cheese, etc.), edible vegetable oils, margarine, vegetable proteins, retort foods, frozen foods, various seasonings (e.g., soybean paste, soy sauce, sauces, etc.) can be manufactured by adding the lactic acid bacteria of the present invention. In addition, in order to use the lactic acid bacteria of the present invention in the form of a food additive, it can be manufactured in the form of a powder or concentrate and used.
[0027]
[0028] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating cognitive dysfunction, comprising Prevotella loescheii as an active ingredient.
[0029] As used herein, the term "cognitive impairment" means a cognitive impairment accompanied by symptoms of memory impairment, attention impairment, time perception ability, spatial perception ability, language impairment, or a combination thereof.
[0030] In one embodiment of the present invention, the cognitive dysfunction is an amyloid beta deposition disease selected from the group consisting of Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia, Huntington's disease dementia, preclinical Alzheimer's disease, and Down syndrome, but is not limited thereto.
[0031] Additionally, in another embodiment of the present invention, the cognitive dysfunction is a tau deposition disease selected from the group consisting of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Pick's disease, and frontotemporal dementia (FTD), but is not limited thereto.
[0032] In one embodiment of the present invention, the cognitive dysfunction may be caused by stress, but is not limited thereto.
[0033] In one embodiment of the present invention, the Prevotella loescheii inhibits the production of amyloid beta protein in brain tissue.
[0034] In one embodiment of the present invention, the amyloid beta protein is a soluble or insoluble amyloid beta protein.
[0035] In one embodiment of the present invention, the amyloid beta protein may be, but is not limited to, Aβ40-, Aβ42-, or a combination thereof.
[0036] In one embodiment of the present invention, the tau protein is a phosphorylated tau protein.
[0037] In one embodiment of the present invention, the Tau protein is Tau13, phosphorylated Tau (Thr231), phospho-Tau (Ser202, Thr205), phospho-Tau (Thr181), phospho-Tau (Thr212, Ser214), phospho-Tau (Ser396), phospho-Tau (Ser422), but is not limited thereto.
[0038] In one embodiment of the present invention, the tau protein is a soluble or insoluble tau protein.
[0039] The strain, which is an effective ingredient of the compositions of the present invention, includes not only the strain isolated and / or purified, but also a culture containing the strain, a lysate of the strain, an extract of the strain, a culture supernatant, a concentrate, a concentrate, a dried product thereof, and also, if necessary, a dilution, a dilution, etc., and includes all states obtained by treating the above-mentioned culture solution and culture.
[0040] The cultivation method, extraction method, separation method, concentration method, drying method, dilution method, etc. of the above-mentioned fungi are not particularly limited.
[0041] The medium for culturing the fungus typically contains milk proteins such as skim milk, whey, and casein, sugars, yeast extract, etc., and any of the general aerobic or anaerobic methods can be used as the culturing method.
[0042] For example, the culture temperature can be set to 35-45℃, and a neutralization culture method can be used during culture, using an alkali such as sodium hydroxide to maintain the pH of the medium from neutral to acidic, for example, at around pH 5-6. In addition to this neutralization culture method, any culture method such as batch culture can be used, and after culture, the culture or its supernatant can be concentrated, dried, diluted, etc., as needed.
[0043] Additionally, the supernatant of the culture and the cells can be separated using centrifugation or membrane separation, and the cells can be recovered in a concentrated state. Furthermore, the cells can be subjected to sonication or enzyme treatment to extract components within the cells, or the culture, its supernatant, cells, or their extracts can be dried. These can be used as effective ingredients of the composition of the present invention.
[0044] When the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier included in the pharmaceutical composition of the present invention is one commonly used in formulation, and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
[0045] The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably administered orally. The pharmaceutical composition of the present invention can be formulated into various oral or parenteral dosage forms, including, but not limited to, the following.
[0046] Oral dosage forms include, for example, tablets, pills, hard / soft capsules, liquids, suspensions, emulsifiers, syrups, granules, elixirs, etc., and these dosage forms may use, in addition to the above-mentioned active ingredients, one or more diluents or excipients such as fillers, bulking agents, wetting agents, disintegrants, lubricants, binders, and surfactants that are commonly used. Disintegrants that can be used include agar, starch, alginic acid or its sodium salt, calcium hydrogen phosphate anhydride, etc., and lubricants that can be used include silica, talc, stearic acid or its magnesium or calcium salt, polyethylene glycol, etc., and binders that can be used include magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidine, low-substituted hydroxypropyl cellulose, etc. In addition, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, etc. can be used as diluents, and in some cases, commonly known boiling mixtures, absorbents, colorants, flavoring agents, sweeteners, etc. can be used together.
[0047] The above composition may be sterilized or may contain preservatives, stabilizers, wetting agents or emulsifying agents, salts for osmotic pressure control, buffers, and other therapeutically useful substances, and may be formulated according to conventional mixing, granulation, or coating methods.
[0048] The appropriate dosage of the pharmaceutical composition of the present invention can be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity.
[0049] The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by placing it in a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains, and by putting it in a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersing agent or stabilizer.
[0050] According to another aspect of the present invention, the present invention provides a composition for improving intestinal microflora comprising Prevotella loescheii as an active ingredient.
[0051] The term "improving intestinal flora" as used herein means reducing the proportion of harmful intestinal bacteria and increasing the proportion of beneficial bacteria.
[0052] The beneficial bacteria may occupy a higher proportion in the intestinal flora of normal people compared to patients with metabolic diseases, and the harmful bacteria may occupy a higher proportion in the intestinal flora of patients with metabolic diseases compared to normal people.
[0053] For example, the improvement in the intestinal flora may be an increase in the proportion of bacteria of the genus Prevotella in the intestinal flora.
[0054] In one embodiment of the present invention, the Prevotella genus fungus includes Prevotella loescheii.
[0055] In one embodiment of the present invention, the harmful bacteria includes Odoribactor splanchnicus.
[0056] The composition of the present invention may be in powder form, and in the case of powder form, it may be coated or uncoated in the form of a capsule. In addition, the composition may be used in the form of preparations for oral administration, such as tablets, hard or soft capsules, liquids, suspensions, etc., and these preparations may be prepared using acceptable conventional carriers, for example, in the case of preparations for oral administration, excipients, binders, disintegrants, lubricants, solubilizers, suspending agents, preservatives, or bulking agents.
[0057] Methods for processing bacteria to provide probiotic preparations are well known in the art, and the form of preparation is not particularly limited as long as the bacteria are alive. For example, after culturing the bacteria, the cell pellet can be recovered and used as is or processed by a desired method, such as concentration or / and lyophilization, for use in the manufacture of pharmaceutical or edible products. Sometimes, the probiotic preparation may undergo an immobilization or encapsulation process to improve its shelf life. Techniques for immobilizing or encapsulating bacteria are well known in the art.
[0058]
[0059] Since the food composition, pharmaceutical composition, and composition for improving intestinal flora according to the above-described aspect of the present invention all commonly contain Prevotella rushii as an active ingredient, the contents of the common composition and features between each invention are equally applicable, and duplicate descriptions are omitted to prevent complexity of this specification.
[0060]
[0061] The present invention relates to a composition for improving long-term memory and cognitive function, comprising intestinal microorganisms as an active ingredient. The composition of the present invention comprises Prevotella loescheii isolated from a healthy animal as an active ingredient, and exhibits excellent efficacy in improving cognitive function and intestinal flora, and thus can be usefully used as a food and therapeutic agent for these purposes.
[0062]
[0063] Figure 1 is a schematic diagram of an experimental method to determine the effect of exercise on microbial changes in mice (offspring of maternal separation) under stress due to maternal separation (MS) and the effect of microbial transplantation on cognitive functions such as long-term memory and spatial learning and memory.
[0064] Figures 2a to 2d show the results of the Morris water maze test, showing spatial learning ability by treatment group.
[0065] Figures 3a to 3d are diagrams showing the results of Western blot analysis for the expression of BDNF, PSD95, and Synatophysin proteins to determine the effect of gut microbiota transplantation on the neuroplasticity of maternal separation (MS) offspring hippocampi of mice that performed exercise.
[0066] Figures 4a to 4d are diagrams showing the results of Western blots for the expression of Bax, Bcl-2, and caspase-3, proteins related to hippocampal apoptosis, to determine the effect of gut microbiota transplantation on apoptosis in the hippocampus of maternal separation (MS) offspring mice that performed exercise.
[0067] Figures 5a and 5b are diagrams showing the results of immunohistochemistry performed on the expression of TUNEL Positive cells, which is DNA fragmentation, to determine the effect of intestinal microbiota transplantation on cell death in the maternal separation (MS) offspring hippocampus of mice that performed exercise.
[0068] Figures 6a and 6b are diagrams showing the results of immunohistochemistry for the expression of Positive DCX cells to determine the effect of intestinal microbiota transplantation on the differentiation of maternal separation (MS) offspring hippocampal neurons in mice that performed exercise.
[0069] Figures 7a to 7g are diagrams showing the results of analyzing the types of intestinal microorganisms in each group to confirm changes in the species diversity of intestinal microorganisms.
[0070] Figures 8a to 8d are diagrams showing the differences in the distribution of microorganisms in each group by analyzing the relative abundance of microorganisms. Figures 8e to 8g are diagrams showing the distribution of strains belonging to the genus Prevotella. Figures 8h and 8i are diagrams showing the distribution of strains belonging to the genus Odoribacter.
[0071] Figure 9 is a schematic diagram of an experiment conducted to determine the effect of single probiotic transplantation on cognitive function in normal mice.
[0072] Figures 10a to 10d are diagrams showing the results of a Morris water maze experiment performed to determine the effect of a single beneficial bacteria transplant on cognitive function in normal mice.
[0073] Figures 11a to 11c are diagrams showing the expression levels of proteins in the hippocampus tissue of mice, a tissue related to memory, to determine the effect of single beneficial bacteria transplantation on cognitive function in normal mice.
[0074] Figures 12a and 12b are diagrams showing BrdU+ / NeuN+ cells in the neurons of the dentate gyrus (dentate gyrus) of the hippocampus of a mouse treated with microorganisms, to confirm the efficacy of administration of Prevotella rushii on changes in neuron production in the hippocampus.
[0075]
[0076] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.
[0077]
[0078] Example
[0079]
[0080] Throughout this specification, "%" used to indicate the concentration of a particular substance is (weight / weight) % for solid / solid, (weight / volume) % for solid / liquid, and (volume / volume) % for liquid / liquid, unless otherwise noted.
[0081]
[0082] Experimental method
[0083]
[0084] 1. Animal model of irritable bowel syndrome
[0085] A mouse model of irritable bowel syndrome (IBS) caused by maternal separation stress was used as an experimental animal. Infant stress affects the central nervous system, inducing visceral hyperalgesia, which in turn triggers IBS. Pregnant mice were purchased from an animal specialty company, and maternal separation was performed daily for three hours from birth to 21 days, with separation occurring at the same time every morning, 8:00 AM.
[0086]
[0087] 2. Aerobic exercise
[0088] High-intensity exercise or prolonged exercise lasting more than an hour increases blood flow to the muscles, which reduces blood flow to the digestive system. This can compromise the intestinal lining and lead to inflammation. Therefore, exercise was performed once a day for 30 minutes, five times a week for four weeks, with a progressively increased load within the low-intensity range. After acclimation training, electrical stimulation was removed to minimize stress.
[0089]
[0090] 3. Fecal microbiota transplantation (FMT)
[0091] The feces of donors who performed aerobic exercise were homogenized in sterile phosphate-buffered saline, centrifuged at 800 g for 2 min, and the supernatant was collected. The diluted fecal supernatant was administered orally at 0.5 mL doses every 3 days for 4 weeks.
[0092]
[0093] 4. Immunohistochemistry - DCX, TUNEL
[0094] After fixing the hippocampal tissue, serial sections were prepared and immunohistochemical analysis was performed.
[0095]
[0096] 5. Western blot - Bax, Bcl-2, caspase-3, BDNF, PSD95, Synatophysin
[0097] Hippocampal tissue was collected and homogenized, then blocked, treated with primary antibodies, and applied with secondary antibodies. Bands were identified using an enhanced chemiluminescence detection system.
[0098]
[0099] 6. Morris water maze test
[0100] The Morris water maze is a widely used test to evaluate learning and memory abilities in rats. The animals are placed in a tank and the escape latency is measured until they find the escape platform, which is recorded as a learning performance score.
[0101]
[0102] 7. Step-through passive avoidance task
[0103] The step-through passive avoidance task is a memory test that utilizes the characteristics of laboratory animals. After learning electrical stimulation, learning memory ability is measured through latency.
[0104]
[0105] 8. Microbiota analysis
[0106] Fresh fecal samples were collected from mice after the behavioral experiment. A DNA extraction kit (Qiagen, Hilden, Germany) was used to isolate fecal microbial DNA. The extracted DNA was quantified using Quent-IT PicoGreen (Invitrogen). Sequencing libraries were prepared according to the Illumina 16S metagenomic sequencing library protocol. Sequencing was performed by Macrogen using the MiSeq platform (Illumina, San Diego, USA). 16S rRNA data were analyzed using QIIME (quantitative insights into microbial ecology) software. Linear discriminant analysis (LDA) effect size (LEfSe) was used to visualize the results and identify distinct taxa.
[0107]
[0108]
[0109] Test results
[0110]
[0111] Example 1: Effects of gut microbiota transplantation in exercise-trained mice on long-term memory and spatial learning and memory in maternally separated (MS) offspring.
[0112] To investigate the effects of exercise on microbial changes in mice (offspring of maternal separation) under stressful conditions due to maternal separation (MS) and the effects of microbial transplantation on cognitive functions such as long-term memory and spatial learning and memory, an experiment was conducted as shown in the schematic diagram in Fig. 1.
[0113] Specifically, the mice were divided into the following groups: a normal group (CON), a group in which exercise was applied to normal mice (CON-Ex), a group in which maternal separation-induced stress model (MS), a group in which fecal microbiota from normal mice were transplanted to mice stressed by maternal separation (MS-CON+FMT), a group in which exercise was applied to mice stressed by maternal separation (MS-Ex), and a group in which fecal microbiota from mice stressed by maternal separation were transplanted to mice stressed by maternal separation (MS-Ex+FMT), and the Morris water maze test was performed to investigate spatial learning and memory.
[0114] The results are shown in Figures 2a to 2d.
[0115] As shown in Figures 2a, 2b, and 2d, the maternal separation (MS) group showed decreased spatial learning ability compared to the other groups. In addition, in the spatial memory test, the maternal separation (MS) group showed decreased spatial memory compared to the normal group (CON), while the gut microbiota transplantation (MS+CON-FMT) group, the exercise (MS+EX) group, and the gut microbiota transplantation of mice that performed exercise (MS+EX-FMT) group showed increased spatial memory. In the comparison of treatment groups, the exercise group and the gut microbiota transplantation group that performed exercise showed a significant increase.
[0116] In addition, as shown in Figure 2c, the long-term memory test using the passive avoidance test showed results similar to the spatial memory results described above.
[0117] Therefore, the results of this study suggest that although maternal separation stress reduces cognitive function in offspring, exercise and gut microbiota transplantation can improve cognitive function. Specifically, gut microbiota transplantation combined with exercise demonstrated improvements in stress-induced cognitive impairment, similar to the effects of exercise itself.
[0118]
[0119] Example 2: Effects of Gut Microbiota Transplantation in Exercise-Exercised Mice on BDNF, PSD95, and Synatophysin in the Hippocampus of Maternally Separated Offspring (MS)
[0120] To investigate the effects of gut microbiota transplantation on the neuroplasticity of maternal separation (MS) offspring hippocampi in mice that performed exercise, we examined the expression of BDNF, PSD95, and Synatophysin proteins using Western blot.
[0121] The results are shown in Figures 3a to 3d.
[0122] Compared to the control group, the maternal separation (MS) group showed decreased expression of hippocampal BDNF, PSD95, and Synatophysin proteins, while the gut microbiota transplantation (MS+CON-FMT), exercise (MS+EX), and exercise-induced gut microbiota transplantation (MS+EX-FMT) groups showed increased expression of hippocampal BDNF, PSD95, and Synatophysin proteins. In a comparison of treatment groups, the expression levels were significantly increased in the exercise and exercise-induced gut microbiota transplantation groups.
[0123] Our results suggest that maternal separation stress reduces hippocampal neuroplasticity in offspring, but that exercise and gut microbiota transplantation can improve hippocampal neuroplasticity. Specifically, exercise-induced gut microbiota transplantation, similar to the effects of exercise itself, improved stress-induced hippocampal neuroplasticity.
[0124]
[0125] Example 3: Effect of gut microbiota transplantation on apoptosis in the hippocampus of offspring mice following maternal separation (MS)
[0126] The present inventors also examined the effect of gut microbiota transplantation on apoptosis in the hippocampus of maternal separation (MS) offspring mice by Western blot analysis to determine the expression of Bax, Bcl-2, and caspase-3, proteins related to hippocampal apoptosis.
[0127] The results are shown in Figures 4a to 4d.
[0128] Compared with the control group, the maternal separation (MS) group showed increased expression of Bax and caspase-3 proteins and decreased expression of Bcl-2 protein in the hippocampus. However, the gut microbiota transplantation group (MS+CON-FMT), the exercise group (MS+EX), and the gut microbiota transplantation group of mice that performed exercise (MS+EX-FMT) showed decreased expression of Bax and caspase-3 and increased expression of Bcl-2 protein compared to the maternal separation (MS) group.
[0129] In a comparison by treatment group, a significant decrease in Bax and caspase-3 expression and an increase in Bcl-2 expression were observed in the group that performed exercise (MS+EX) and the group that transplanted intestinal microbiota of mice that performed exercise (MS+EX-FMT).
[0130] Our results suggest that maternal separation stress increases apoptosis in the offspring hippocampus, but that exercise and gut microbiota transplantation can reduce hippocampal apoptosis. Specifically, gut microbiota transplantation in exercised mice suppressed stress-induced hippocampal apoptosis, similar to the direct effects of exercise.
[0131]
[0132] Example 4: Effect of gut microbiota transplantation on cell death in the hippocampus of offspring after maternal separation (MS) in mice that performed exercise.
[0133] To investigate the effect of gut microbiota transplantation on maternal separation (MS) offspring hippocampal cell death in mice that exercised, we performed immunohistochemistry on the expression of TUNEL Positive cells, a marker of DNA fragmentation.
[0134] The results are shown in Figures 5a and 5b.
[0135] Compared to the control group, the maternal separation (MS) group showed increased expression of positive TUNEL cells in the hippocampus, while the gut microbiota transplantation (MS+CON-FMT), exercise (MS+EX), and gut microbiota transplantation of mice that performed exercise (MS+EX-FMT) groups showed decreased expression of positive TUNEL cells in the hippocampus.
[0136] In a comparison between treatment groups, there was a significant decrease in the exercise and gut microbiota transplant groups of mice that performed exercise.
[0137] Therefore, the results of this study revealed that maternal separation stress increased apoptosis in the offspring hippocampus, but exercise and gut microbiota transplantation reduced hippocampal apoptosis. Specifically, gut microbiota transplantation in mice that exercised suppressed stress-induced hippocampal apoptosis, similar to the direct effect of exercise.
[0138]
[0139] Example 5: Effect of gut microbiota transplantation in mice that exercised on maternal separation (MS) offspring hippocampal cell differentiation.
[0140] The present inventors performed immunohistochemistry on the expression of positive DCX cells to investigate the effect of gut microbiota transplantation on the differentiation of maternal separation (MS) offspring hippocampal neurons in mice that performed exercise.
[0141] The results are shown in Figures 6a and 6b.
[0142] Compared to the control group, the maternal separation (MS) group showed a decrease in the expression of Positive DCX cells in the hippocampus, while the expression of Positive DCX cells increased in the gut microbiota transplantation (MS+CON-FMT), exercise (MS+EX), and gut microbiota transplantation of mice that performed exercise (MS+EX-FMT) groups.
[0143] In a comparison between treatment groups, there was a significant increase in the intestinal microbiota transplant group of mice that performed exercise and exercise.
[0144] Therefore, the results of this study suggest that although maternal separation stress reduces hippocampal cell differentiation in offspring, exercise and gut microbiota transplantation can improve hippocampal cell differentiation. Specifically, gut microbiota transplantation following exercise was found to enhance the stress-induced decrease in hippocampal neuronal differentiation, similar to the effects of direct exercise.
[0145]
[0146] Example 6: Changes in species diversity (alpha and beta-diversity) of gut microbiota by group
[0147] To confirm changes in the species diversity of intestinal microorganisms in animal models, the inventors analyzed the types of intestinal microorganisms in each group.
[0148] The results are shown in Figures 7a to 7g.
[0149] As shown in Figures 7a to 7g, there was no significant difference in species diversity between groups, but according to the results shown in Chao-1, the MS group showed a significant decrease in species richness compared to the other groups.
[0150] Additionally, the results of comparing the similarity of microorganisms within each group showed that microorganisms reflecting the characteristics of the group were distributed.
[0151]
[0152] Example 7: Average distribution of microorganisms in each group
[0153] In addition, the inventors of the present invention confirmed the relative abundance at the genus level and species level to find out the average distribution of microorganisms in each group (Figs. 8a and 8b), and then performed LEfSe analysis to find out the difference in distribution of microorganisms in each group. As a result, microorganisms with an LDA score of 3 or higher were as shown in Fig. 8d.
[0154] According to Figures 8e to 8g, among these, Prevotella (G) significantly decreased in the maternal separation (MS) group, but significantly increased in the group transplanted with gut microbiota from healthy or exercised mice after maternal separation. Specifically, Prevotella loescheii (S) showed a similar trend between the groups as Prevotella (G), whereas Prevotella shahii (S) was not found in any group. It was confirmed that Prevotella stercorea (S) was found only in the group transplanted with gut microbiota from healthy or exercised mice.
[0155] On the other hand, according to Figures 8h to 8i, Odoribacter (G) significantly increased in the maternally separated group and significantly decreased in the group that exercised after maternally separated and the group that was transplanted with intestinal microflora from exercised mice. Odoribactor splanchnicus (S) showed a similar trend to Odoribacter (G).
[0156]
[0157] Example 8: Effects of single probiotic transplantation on cognitive function in normal mice
[0158] 8-1: Morris Underwater Training
[0159] In addition, the inventors of the present invention performed an experiment as shown in the schematic diagram of Fig. 9 to determine the effect of single probiotic transplantation on cognitive function in normal mice.
[0160] Briefly, 5-week-old C57BL / 6J (DBL) mice were acclimated for 4 weeks, and then orally administered Prevotella loescheii strain deposited under accession number KCCM 42828 for 5 weeks starting at 9 weeks of age. The strain was purchased from KCCM. Oral administration was divided into 4 groups of 10 mice each by concentration (control group, concentration 0.5*10 9 CFU / mouse, concentration 1*10 9 CFU / mouse, concentration 1.5 *10 9 The mice were divided into 10 CFU / mouse and treated. From the age of 14 weeks, the mice were given the Morris water maze test, which involved finding an escape platform in water, three times a day for five days, and then tested for 24 hours on the sixth day.
[0161] The results are shown in Figures 10a to 10d.
[0162] Figure 10a is a diagram showing the movement path of the mouse during the test. Figure 10b shows the time when the mouse first reached the escape position during the test, Figure 10c shows the time spent in the SW zone during the test, and Figure 10d shows the distance moved in the SW zone during the test (CTL = control group; D0.5 = concentration 0.5; D1.0 = concentration 1.0; D1.5 = concentration 1.5).
[0163] As shown in Figures 10a to 10d, compared to the control group, the time taken to reach the escape platform decreased in the D1.0 and D1.5 groups, and the time spent on the escape platform tended to increase.
[0164] Therefore, it was found that the group administered Pribotelli rushii, a single beneficial bacterium of the present invention, accession number KCCM 42828, had an effect of improving spatial perception cognitive function.
[0165]
[0166] 8-2: Examination of molecular biological changes in the mouse hippocampus (memory)
[0167] The present inventors also investigated molecular biological changes in hippocampal tissue after oral administration of microorganisms for 5 weeks using the aforementioned C57BL / 6J mice. Specifically, the expression levels of PSD95, Synaptophysin, and BDNF proteins in the hippocampus were confirmed. PSD95 is a protein that regulates synaptic density, Synaptophysin is a major vesicle protein, also known as P38, and BDNF is a protein corresponding to a neurotrophic factor. (CTL = control group; D0.5 = concentration 0.5; D1.0 = concentration 1.0; D1.5 = concentration 1.5.)
[0168] The results are shown in Figures 11a to 11c.
[0169] As shown in Figures 11a to 11c, compared to the control group, the D0.5, D1.0, and D1.5 groups all showed a tendency for the expression levels of PSD95, Synaptophysin, and BDNF proteins in the hippocampus to increase.
[0170] Therefore, in the case of the group administered with Pribotelli rushii, a single beneficial bacterium of the present invention, accession number KCCM 42828, there was an increase in the expression of neuronal markers in the hippocampus related to memory, and thus it was found that there was an effect of improving cognitive function.
[0171]
[0172] In addition, the inventors of the present invention observed BrdU+ / NeuN+ cells in the neurons of the dentate gyrus of the hippocampus of mice treated with microorganisms by fluorescent immunostaining in order to confirm the efficacy of administration of Prevotella rushii of the present invention on changes in neuron production in the hippocampus, and analyzed the ratio thereof.
[0173] The results are shown in Figures 12a and 12b. In Figure 12a, BrdU immunoreactivity (green), NeuN immunoreactivity (red), and arrows indicate BrdU+ / NeuN+ cells (CTL=control group; D0.5=concentration 0.5; D1.0=concentration 1.0; D1.5=concentration 1.5. Scale bars, 20 μm and 100 μm, respectively).
[0174] As shown in Figures 12a and 12b, BrdU+ / NeuN+ cells tended to increase in the microbial treatment group compared to the control group, but there was no significant difference.
Claims
1. A food composition for improving long-term memory and cognitive function, comprising Prevotella loescheii as an active ingredient.
2. A food composition according to claim 1, wherein the Prevotella loescheii is isolated from the intestine of an animal.
3. A food composition according to claim 1, wherein the Prevotella loescheii is a strain deposited under accession number KCCM 42828.
4. A food composition according to claim 1, wherein the cognitive function is memory, attention, time perception, spatial perception, language, judgment, or a combination thereof.
5. A food composition according to claim 1, wherein the food is a health functional food.
6. A pharmaceutical composition for preventing or treating cognitive dysfunction, comprising Prevotella loescheii as an active ingredient.
7. A pharmaceutical composition according to claim 6, wherein the Prevotella loescheii is a strain deposited under accession number KCCM 42828.
8. A pharmaceutical composition according to claim 6, wherein the cognitive dysfunction is caused by stress.
9. A composition for improving intestinal flora, comprising Prevotella loescheii as an active ingredient.
10. A composition for improving intestinal flora in claim 9, wherein the improvement of intestinal flora is to increase the proportion of Prevotella genus bacteria in the intestinal flora.
11. A composition for improving intestinal microflora in claim 10, wherein the Prevotella genus bacteria includes Prevotella loescheii.
Citation Information
Patent Citations
Methods for treating autism spectrum disorder and associated symptoms
US20190358274A1
Compositions and Methods for Detecting and Treating Brain Injury Associated Fatigue and Altered Cognition (BIAFAC)
US20210275608A1
Therapeutic compositions and methods of using serotonin modulating microbiome-based interventions to treat serotonin-related diseases or disorders
WO2020264390A2
